MedCity News January 26, 2025
Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next-generation obesity drugs. Analysts say the lack of details safety and tolerability details make it difficult to fully assess the preliminary Phase 1b/2a results.
A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge over the company’s main metabolic medicines rival, Eli Lilly.
The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment...
Today's Sponsors
Today's Sponsor